scholarly journals An open, self-controlled study on the efficacy of topical indoxacarb for eliminating fleas and clinical signs of flea-allergy dermatitis in client-owned dogs in Queensland, Australia

2014 ◽  
Vol 25 (3) ◽  
pp. 195-e49 ◽  
Author(s):  
Petr Fisara ◽  
Roger M. Sargent ◽  
Michael Shipstone ◽  
Andrew von Berky ◽  
Janet von Berky
Keyword(s):  
Clinical Signs ◽  
Controlled Study ◽  
Flea Allergy Dermatitis ◽  
Flea Allergy

scholarly journals Successful Treatment of a Multi-Drug-Resistant Severely Pruritic Hypersensitivity Dermatitis in a Cat

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Urszula Rzeszutek
Keyword(s):  
Essential Fatty Acids ◽  
Clinical Signs ◽  
Treatment Modalities ◽  
Drug Resistant ◽  
Retroviral Infection ◽  
First Case ◽  
Flea Allergy Dermatitis ◽  
Adverse Food Reaction ◽  
Serology Test ◽  
Flea Allergy

A 3-year-old neutered female domestic shorthair cat was presented with a severely pruritic dermatitis. After exclusion of flea allergy dermatitis, ectoparasite infestation, retroviral infection, neoplasia, and cutaneous adverse food reaction, a diagnosis of nonflea, nonfood hypersensitivity dermatitis (NFNFHD) was made. The resolution of complicating bacterial infection and yeast overgrowth did not improve the animal’s condition. Numerous antipruritic treatment modalities used during the investigation proved unsuccessful, including anti-inflammatory and immunosuppressive prednisolone doses, oclacitinib, antihistamines, ciclosporin A, and supplementation with essential fatty acids. Allergen-specific serology test results were negative. Treatment with oral dexamethasone allowed a complete resolution of clinical signs. The cat has been successfully maintained in remission for over 12 months. To the author’s knowledge, this is the first case report of a cat with multi-drug-resistant NFNFHD treated successfully with dexamethasone.

Efficacy of selamectin in the treatment and control of clinical signs of flea allergy dermatitis in dogs and cats experimentally infested with fleas

2003 ◽  
Vol 223 (5) ◽  
pp. 639-644 ◽  
Author(s):  
Sandy K. Dickin ◽  
Tom L. McTier ◽  
Martin G. Murphy ◽  
Ross Bond ◽  
Ian S. Mason ◽  
...  
Keyword(s):  
Clinical Signs ◽  
Flea Allergy Dermatitis ◽  
Flea Allergy ◽  
And Control

scholarly journals Conventional Photodynamic Therapy versus Fractional CO2 Laser Assisted Photodynamic Therapy in Treatment of Onychomycosis

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
M M A Abdallah ◽  
M T Mahmoud ◽  
M Y Soltan ◽  
M M M Abughali
Keyword(s):  
Photodynamic Therapy ◽  
Clinical Signs ◽  
Diagnostic Techniques ◽  
Aspergillus Species ◽  
Controlled Study ◽  
Fungal Culture ◽  
Mycological Cure ◽  
University Hospitals ◽  
Humid Climate ◽  
Dermatology Department

Abstract Background Onychomycosis is a common persistent infection of the nail unit by fungi either dermatophytes, yeasts or non-dermatophyte molds (NDMs). It is classified clinically to distal and lateral subungual onychomycosis (DLSO), superficial white onychomycosis (SWO), proximal subungual onychomycosis (PSO), candidal onychomycosis, endonyx onychomycosis and total dystrophic onychomycosis (TDO). Onychomycosis is commonly confirmed by clinical examination side by side with regular diagnostic techniques such as direct microscopy and fungal culture, which are considered the golden are considered the golden standards of diagnosis. Aim of the Work to evaluate two PDT approaches in the treatment of onychomycosis. The study will compare the effect of PDT using conventional method versus fractional CO2 assisted PDT for achievement of a clinical and mycological cure in cases of onychomycosis. Patients and Methods we conducted a right-left controlled study, on 21 patients with at least 2 toenails onychomycosis in the same patient. These patients were recruited from outpatient clinic of dermatology department at Ain Shams University Hospitals. The study was conducted during the period from December 2016 till June 2017. Twenty-one patients (4 males and 17 females) with clinical signs of toenail onychomycosis were enrolled in the study. The diagnosis was confirmed via laboratory studies. Results in our study, we found that Aspergillus species were the most common causative organisms of OM followed by and this is possibly because the non NDMs are more frequent in tropical and subtropical areas with a hot and humid climate. Conventional PDT and fractional CO2-assisted PDT have an antifungal activity as manifest by a mycological cure rate of 57.1% and 76.2% in OM cases respectively. Fractional CO2-assisted PDT was superior to conventional PDT as regard the clinical improvement in nail appearance and patient satisfaction. Conclusion non-dermatophyte molds are important and common pathogens in toenail onychomycosis. Aspergillus species play an important role as pathogens for toenail onychomycosis in Egypt.

Flea allergy dermatitis: the continued challenge

2012 ◽  
Vol 3 (6) ◽  
pp. 350-356 ◽  
Author(s):  
Hany M Elsheikha
Keyword(s):  
Flea Allergy Dermatitis ◽  
Flea Allergy

German shepherd dog pyoderma: a prospective study of 12 dogs

1997 ◽  
Vol 33 (4) ◽  
pp. 355-363 ◽  
Author(s):  
Rosser EJJr
Keyword(s):  
Atopic Dermatitis ◽  
Food Allergy ◽  
Underlying Disease ◽  
German Shepherd ◽  
German Shepherd Dog ◽  
Flea Allergy Dermatitis ◽  
Flea Allergy ◽  
A Prospective Study ◽  
Systemic Antibiotics ◽  
Idiopathic Disease

Twelve German shepherd dogs, each diagnosed as having a recurrent or refractory deep pyoderma (i.e., German shepherd dog pyoderma [GSP]), were evaluated for several parameters over a six-year period. Results indicated that GSP could be associated with flea allergy dermatitis, atopic dermatitis, food allergy, cell-mediated immunodeficiency, or hypothyroidism, or could be an idiopathic disease. The combination of diseases present for a given dog varied from case to case. Adequate control of the pyoderma was achieved only after each identified underlying disease was treated specifically, along with aggressive concurrent medical therapy using systemic antibiotics and medicated baths.

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20

Blood ◽  
2003 ◽  
Vol 101 (10) ◽  
pp. 3818-3826 ◽  
Author(s):  
Domenico Sansonno ◽  
Valli De Re ◽  
Gianfranco Lauletta ◽  
Felicia Anna Tucci ◽  
Mauro Boiocchi ◽  
...  
Keyword(s):  
Hepatitis C ◽  
B Cell ◽  
Clinical Signs ◽  
Mixed Cryoglobulinemia ◽  
Controlled Study ◽  
Chimeric Antibody ◽  
Interferon Α ◽  
Hcv Rna ◽  
Rapid Improvement ◽  
Antibody Treatment

Abstract A controlled study has been carried out to assess the efficacy of rituximab, a chimeric antibody that binds to the B-cell surface antigen CD20, in 20 patients with mixed cryoglobulinemia (MC) and hepatitis C virus (HCV)–positive chronic active liver disease, resistant to interferon α (IFN-α) therapy. They received an intravenous infusion of 375 mg/m2 rituximab once a week for 4 consecutive weeks. Infusion of rituximab had a good safety profile and no severe side effects were reported. Sixteen patients (80%) showed a complete response (CR), characterized by rapid improvement of clinical signs (disappearance of purpura and weakness arthralgia and improvement of peripheral neuropathy), and decline of cryocrit. CR was associated with a significant reduction of rheumatoid factor (RF) activity and anti-HCV antibody titers. Decline of IgG anti-HCV titers in the cryoprecipitates was usually associated with a favorable response (r = 0.81; P < .005). No differences in the dynamics of B-cell depletion and recovery were found between responders and nonresponders. Molecular monitoring of the B-cell response revealed disappearance/deletion of peripheral clones in the responders and great stability in the nonresponders. Rituximab had a deep impact on hepatitis C viremia; HCV RNA increased approximately twice the baseline levels in the responders, whereas it remained much the same in the nonresponders. Twelve (75%) of 16 responders remained in remission throughout the follow-up. The results indicate that rituximab has clinical and biologic activity in patients with HCV+ MC. However, in view of the increased viremia in the responders, additional modes of application and combination of rituximab with other agents need to be investigated.

Comparison of Periodontitis and Root Replacement in Cat Teeth with Resorptive Lesions

2002 ◽  
Vol 19 (2) ◽  
pp. 71-75 ◽  
Author(s):  
Gregg A. DuPont ◽  
Linda J. DeBowes
Keyword(s):  
Periodontal Ligament ◽  
Clinical Signs ◽  
Controlled Study ◽  
Focal Lesion ◽  
Retrospective Case ◽  
Radiographic Appearance

Cat teeth with resorptive lesions and periodontitis may have a distinctly different clinical and radiographic appearance compared with teeth that have focal, lesion-associated gingivitis. A retrospective, case-controlled study was performed to determine the occurrence of root replacement in cats with resorptive lesions and associated periodontitis. Of 543 teeth evaluated with resorptive lesions, radiographic and/or clinical signs of periodontitis were identified in 236 (43.5 %) teeth. Periodontitis was present in 43 of 275 (15.6 %) teeth with root replacement and 193 of 268 (72.0 %) teeth that had normal radiodensity and maintenance of the periodontal ligament. There was a significantly lower occurrence of root replacement in cat teeth with resorptive lesions and periodontitis.

Effect of Saccharomyces boulardii in dogs with chronic enteropathies: double-blinded, placebo-controlled study

2017 ◽  
Vol 182 (9) ◽  
pp. 258-258 ◽  
Author(s):  
Simona D’Angelo ◽  
Federico Fracassi ◽  
Francesca Bresciani ◽  
Roberta Galuppi ◽  
Alessia Diana ◽  
...  
Keyword(s):  
Body Condition Score ◽  
Activity Index ◽  
Clinical Signs ◽  
Saccharomyces Boulardii ◽  
Controlled Study ◽  
Clinical Activity ◽  
Short Term ◽  
Chronic Enteropathies ◽  
Healthy Dogs ◽  
Double Blinded

Saccharomyces boulardii is used to treat acute and chronic enteropathies in humans, but to date, no studies have evaluated the use of this yeast in dogs. The current study, a prospective non-randomised, double-blinded, placebo-controlled study, evaluated the effects of S boulardii in healthy dogs and dogs with chronic enteropathies (CE). Four healthy dogs and 20 dogs with CE were included. In healthy dogs, S boulardii was administered for 10 days. Possible short-term adverse effects were recorded, and quantitative stool cultures for yeasts were performed. In dogs with CE, S boulardii or a placebo was administered in addition to standard treatment protocols. Canine Chronic Enteropathy Clinical Activity Index, abdominal ultrasonography, gastroenteroscopy and histology were performed at the time of diagnosis and after 60 days of treatment. In healthy dogs, S boulardii reached a steady state in five days and was completely eliminated on day 4 after administration. No short-term side effects were seen. Clinical activity index, stool frequency, stool consistency and body condition score improved significantly in dogs with CE receiving S boulardii versus the placebo. In conclusion, S boulardii can be safely used in dogs with CE and seems to achieve better control of clinical signs than standard therapy alone.

Sign in / Sign up

Export Citation Format

Share Document